Treating diabetes and hypertension is also mandatory to control CKD and, as largely described, the introduction of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is recommended to potentiate nephroprotection [18–23]. The gene discussed is ACE; the disease is hypertensive disorder.